The Mulligan Lab investigates the innate and adaptative immune responses to pathogens and vaccines by studying how the human body successfully reacts to vaccines and battles infections, and conversely, how infectious pathogens escape immune surveillance. Our overarching goal is to translate basic scientific knowledge to support the development of effective vaccines, therapeutic products, diagnostics, and predictive markers intended for clinical use.
On March 11, 2020, NYU Langone’s Vaccine Center enrolled their first patient infected with SARS-CoV-2 (the virus that causes COVID-19) into our investigator-led study protocol. As part of our investigator-led research, we have now conducted more than 1,500 visits on participants across three of our clinical sites (NYU Langone’s Manhattan campus, NYU Langone Hospital—Brooklyn, and NYC Health + Hospitals/Bellevue) to study the immune responses to SARS-CoV-2 and COVID-19 vaccination. The Mulligan Lab is currently focusing its research on providing much-needed information on those individuals’ immune responses to the virus, vaccines, and breakthrough infections.
In addition to SARS-CoV-2, the Mulligan Lab is conducting research on other pathogens, such as influenza. The Mulligan Lab is involved in a seven-year funded study with the Stop Flu NYU cohort study, which examines molecular signatures correlating with vaccine responses and antibody responses induced by vaccination and breakthrough infections.
Mark J. Mulligan, MD
Alexandria Center for Life Science — West Tower
430 East 29th Street, 3rd Floor, Room 304
New York, NY 10016
Office: (212) 263-9410
Lab: (212) 263-0905